Cipla's Lenalidomide ANDA213165 Receives AP Status from FDA
Cipla's application for lenalidomide has received an Abbreviated Approval (AP) status from the FDA.
Published: July 30, 2026
Updated: July 30, 2026
Author: Humanexa Intelligence
Therapeutic area: Hematology / Multiple Myeloma
Asset: Cipla
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Cipla
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
Cipla's receipt of Abbreviated Approval (AP) for lenalidomide signifies a potential shift in the competitive landscape of multiple myeloma treatments. This could lead to increased pricing pressures and necessitate strategic adjustments from existing market players.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for the launch timeline and market uptake of Cipla's lenalidomide product.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.